Verve Therapeutics, Inc. Quarterly Marketable Securities, Current in USD from Q4 2020 to Q2 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of investment in marketable security, classified as current.
Summary
Verve Therapeutics, Inc. quarterly Marketable Securities, Current history and growth rate from Q4 2020 to Q2 2024.
  • Verve Therapeutics, Inc. Marketable Securities, Current for the quarter ending June 30, 2024 was $434M, a 10.7% increase year-over-year.
Marketable Securities, Current, Quarterly (USD)
Marketable Securities, Current, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q2 2024 $434M +$42M +10.7% Jun 30, 2024 10-Q 2024-08-08
Q1 2024 $462M +$37.2M +8.76% Mar 31, 2024 10-Q 2024-05-08
Q4 2023 $418M -$21.6M -4.92% Dec 31, 2023 10-Q 2024-08-08
Q3 2023 $407M +$133M +48.7% Sep 30, 2023 10-Q 2023-11-07
Q2 2023 $392M +$172M +77.8% Jun 30, 2023 10-Q 2023-08-10
Q1 2023 $425M +$193M +83.3% Mar 31, 2023 10-Q 2023-05-15
Q4 2022 $439M +$143M +48.4% Dec 31, 2022 10-K 2024-02-27
Q3 2022 $274M +$32.6M +13.5% Sep 30, 2022 10-Q 2022-11-07
Q2 2022 $221M +$190M +631% Jun 30, 2022 10-Q 2022-08-09
Q1 2022 $232M Mar 31, 2022 10-Q 2022-05-10
Q4 2021 $296M +$233M +369% Dec 31, 2021 10-K 2023-03-02
Q3 2021 $241M Sep 30, 2021 10-Q 2021-11-10
Q2 2021 $30.2M Jun 30, 2021 10-Q/A 2021-08-16
Q4 2020 $63.1M Dec 31, 2020 10-K 2022-03-14
* An asterisk sign (*) next to the value indicates that the value is likely invalid.